Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7325971 | 0.98 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2SIGMAR1HRH1 | |
| Hydrochloric Acid SCHEMBL5881222 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2SIGMAR1HRH1 | |
| Hydrochloric Acid SCHEMBL7453458 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2HRH3POLB | |
| SCHEMBL7321964 | 0.84 | HRH3 (0.64) | SIGMAR1HRH3 | |
| SCHEMBL7326091 | 0.84 | HRH3 (0.67) | SMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL27431543 | 0.83 | SIGMAR1 (0.64) | SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL9528342 | 0.83 | HRH3 (0.65) | SMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL7326809 | 0.82 | SIGMAR1 (0.49) | SIGMAR1HRH3 | |
| SCHEMBL7323336 | 0.82 | HRH3 (0.44) | SIGMAR1HRH3SLC6A4 | |
| SCHEMBL9370762 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2SIGMAR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | AMPLA PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | ADRB3, FFAR3, SLC6A4 | KDM4E 3973/4885ALDH1A1 2779/4885SMN1; SMN2 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.